<< Back To Search

A Study of WVT078 in Patients With Multiple Myeloma (MM)

Notify the Multiple Myeloma Research Foundation You Are Interested In This Trial


Third Opinion Trial Synopsis:
Doctors are doing a study to figure out how much medicine is safe to use by itself and with another medicine for people with a type of cancer called Multiple Myeloma. They want to find out what amount of the medicine won't make people sick.
*Third Opinion AI Generated Synopsis

Trial Summary
The design of a phase I, open-label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent WVT078 alone and in combination with WHG626 in patients relapses and/or refractory Multiple Myeloma (MM)

Locations & Contact

Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?